Sumit Aggarwal, Eloxx Pharmaceuticals president and CEO
September 15, 2022 10:53 AM EDTUpdated September 16, 08:14 AM
R&D

Eloxx re­ports PhII cys­tic fi­bro­sis fail as the biotech weighs its op­tions

Paul Schloesser

Associate Editor

A rare dis­ease biotech has fall­en short in a clin­i­cal tri­al — and in­vestors are none too hap­py about it.

Eloxx Phar­ma­ceu­ti­cals re­port­ed Wednes­day that its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

A service from the Financial Times